• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [300 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2025 Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to managing people with cervical cancer]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) – benefit assessment according to §35a Social Code Book V]
2024 National Institute for Health and Care Excellence (NICE) Linzagolix for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 996
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: screening for cancers, chronic diseases and STBBIs]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Addendum to Project A23-143]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: unusual vaginal discharge - diagnostic measures and pharmacological treatment]
2024 NIHR Health Technology Assessment programme Cerclage suture type to prevent pregnancy loss in women requiring a vaginal cervical cerclage: the C-STICH RCT
2024 Norwegian Institute of Public Health (NIPH) [Robot assisted hysterectomy: A health technology assessment]
2024 Health Technology Wales (HTW) Robot-assisted benign gynaecological surgery
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (endometrial cancer) – benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (maintenance in combination with durvalumab; endometrial cancer) – benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V]
2024 NIHR Health Technology Assessment programme Cerclage suture type to prevent pregnancy loss in women requiring a vaginal cervical cerclage: the C-STICH RCT
2024 NIHR Health and Social Care Delivery Program Gynaecological cancer surveillance for women with Lynch syndrome: systematic review and cost-effectiveness evaluation
2024 Agency for Care Effectiveness (ACE) Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
2024 Haute Autorite de sante (HAS) [Evaluation of high-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V]
2024 Basque Office for Health Technology Assessment (OSTEBA) [Use of self-sampling for the detection of human papillomavirus in cervical cancer screening]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2024 National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 963
2024 Norwegian Institute of Public Health (NIPH) [Robot–assisted hysterectomy for benign conditions: A rapid health technology assessment]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2023 Ontario Health Robotic-assisted hysterectomy for endometrial cancer in people with obesity
2023 Ontario Health Robotic-assisted hysterectomy for endometrial cancer in people with obesity: a health technology assessment
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Access routes of hysterectomy - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Myomectomy versus no treatment - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [UAE and MRgFUS versus myoma enucleation - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023 NIHR Health Technology Assessment programme Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study
2023 National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 885
2023 National Institute for Health and Care Excellence (NICE) Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal). NICE technology appraisal guidance 901
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Addendum to Commission A22-70]
2023 National Institute for Health and Care Excellence (NICE) Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer. NICE technology appraisal guidance 904
2023 National Institute for Health and Care Excellence (NICE) Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 914
2023 NIHR Health Technology Assessment programme Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding: the UCON randomised controlled trial and mechanism of action study
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [At a glance: screening and management algorithm management of precancerous lesions - cervical cancer and population-based screening]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V]
2023 National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2022 National Institute for Health and Care Excellence (NICE) Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 779
2022 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency ablation for treatment of symptomatic uterine myomas]
2022 NIHR Health Technology Assessment programme Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT
2022 National Institute for Health and Care Excellence (NICE) Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 832
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) - Addendum to Commission A21-164]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Benefit assessment according to § 35a SGB V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022 Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Addendum to commission H21-14]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Second addendum to commission H21-14]
2022 Institute for Clinical Effectiveness and Health Policy (IECS) [Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions]
2021 Norwegian Institute of Public Health (NIPH) [Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2021 NIHR Health Technology Assessment programme Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [High frequency ablation of the endometrium using a mesh electrode in patients with menorrhagia]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Second addendum to commission A21-84]
2021 National Institute for Health and Care Excellence (NICE) Laparoscopic removal of uterine fibroids with power morcellation. NICE interventional procedures guidance 703
2021 National Institute for Health and Care Excellence (NICE) Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids. NICE interventional procedures guidance 704
2021 Malaysian Health Technology Assessment (MaHTAS) HPV vaccine - an update
2021 National Institute for Health and Care Excellence (NICE) Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids. NICE interventional procedures guidance 689
2021 National Institute for Health and Care Excellence (NICE) Minimally invasive radical hysterectomy for early stage cervical cancer. NICE interventional procedures guidance 686
2020 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Intrauterine ultrasound-guided transcervical radiofrequency ablation
2020 National Institute for Health and Care Excellence (NICE) Testing strategies for Lynch syndrome in people with endometrial cancer. NICE diagnostics guidance 42
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Intrauterine ultrasound-guided radiofrequency ablation
2020 Canary Health Service [HPV vaccination in adolescent boys: cost-effectiveness and budget impact]
2020 NIHR Health Technology Assessment programme Surgical interventions for uterine prolapse and for vault prolapse: the two VUE RCTs
2020 Canary Health Service [Liquid biopsy for the detection of ovarian or endometrial cancer in samples taken from the Pap smear: PapSEEK]
2019 National Institute for Health and Care Excellence (NICE) Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids. NICE interventional procedures guidance 657
2019 Canadian Agency for Drugs and Technologies in Health (CADTH) HPV testing for primary cervical cancer screening: a health technology assessment
2019 National Institute for Health and Care Excellence (NICE) Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth. NICE interventional procedures guidance 639
2019 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids - 2nd addendum to commission H16-02B]
2018 NIHR Health Technology Assessment programme Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation
2018 Adelaide Health Technology Assessment (AHTA) Heritable mutations which increase risk in colorectal and endometrial cancer
2018 National Institute for Health and Care Excellence (NICE) Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina. NICE interventional procedures guidance 608
2018 National Institute for Health and Care Excellence (NICE) Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I. NICE diagnostics guidance 32
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Invitation and decision aid for cervical cancer screening]
2017 NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study results from the PROSPECT Study
2017 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: comparison of cervical cancer screening strategies involving the human papillomavirus screening test (HPV test) or gynecological cytology (Pap test)]
2017 Andalusian Health Technology Assessment Area (AETSA) [Rapid response: Effectiveness and safety of hyperthermia in combination with radiation therapy and/or chemotherapy in the treatment of breast, cervix and rectum cancer]
2017 National Institute for Health and Care Excellence (NICE) Transvaginal mesh repair of anterior or posterior vaginal wall prolapse. NICE interventional procedures guidance 599
2017 National Institute for Health and Care Excellence (NICE) Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse. NICE interventional procedures guidance 581
2017 National Institute for Health and Care Excellence (NICE) Infracoccygeal sacropexy using mesh to repair uterine prolapse. NICE interventional procedures guidance 582
2017 National Institute for Health and Care Excellence (NICE) Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse. NICE interventional procedures guidance 584
2017 National Institute for Health and Care Excellence (NICE) Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse. NICE interventional procedures guidance 577
2017 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Hysterectomy, endometrial ablation and hormone-releasing intrauterine devices for heavy menstrual bleeding
2017 Agency for Healthcare Research and Quality (AHRQ) Management of uterine fibroids
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids: Assessment according to §137h Social Code Book V]
2017 HAYES, Inc. Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy orhysterectomy
2017 Health Information and Quality Authority (HIQA) Health technology assessment of human papillomavirus testing as the primary screening method for prevention of cervical cancer
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine myoma (Addendum to Commissions E14-04 and E14-05)]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine myoma: (2. Addendum to Commissions E14-04 and E14-05)]